› navigate
Cynthia Lavoie

General Partner (based in Montreal)

Dr. Cynthia Lavoie

General Partner (based in Montreal)

Dr. Lavoie is a General Partner with TVM Life Science Management Inc. She is located in Montreal and is responsible for the  investment strategy in Canada and the management of  portfolio companies in the US and Canada. Cynthia serves on the boards of Anchor Therapeutics and Kaneq Bioscience. She was previously with VG Partners, a large Canadian private equity firm, where her most recent role was as Partner and head of life sciences. She served on the boards of investee companies Aegera Therapeutics, Cytochroma, Interface Biologics, Trillium Therapeutics and Zelos Therapeutics, among others. During her tenure, Cynthia had a direct role in the sale of VisualSonics, an imaging company, to SonoSite Inc., and Targanta Therapeutics to The Medicines Company.

Prior to joining VG Partners, Cynthia was a marketing strategy consultant with public company Vasogen (acquired by Intellipharmaceutics) and an Investment Program Manager with the Ontario Genomics Institute seeding early stage investments. An accomplished academic, Dr. Lavoie is an active participant on proof of principal granting committees for regional and national commercialization grants. She has ten years of research experience at McGill University and the University of Texas Southwestern Medical Center as well as an MBA from the Rotman School of Management.